1
|
Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, Tannir NM, Budde LE, Harrison SJ, Klobuch S, Patel SS, Meza L, Dequeant ML, Ma A, He QA, Williams LM, Keegan A, Gurary EB, Dar H, Karnik S, Guo C, Heath H, Yuen RR, Morrow PK, Agarwal N, Srour SA. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discov 2024:OF1-OF14. [PMID: 38583184 DOI: 10.1158/2159-8290.cd-24-0102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Revised: 03/08/2024] [Accepted: 03/22/2024] [Indexed: 04/09/2024]
Abstract
Therapeutic approaches for clear cell renal cell carcinoma (ccRCC) remain limited; however, chimeric antigen receptor (CAR) T-cell therapies may offer novel treatment options. CTX130, an allogeneic CD70-targeting CAR T-cell product, was developed for the treatment of advanced or refractory ccRCC. We report that CTX130 showed favorable preclinical proliferation and cytotoxicity profiles and completely regressed RCC xenograft tumors. We also report results from 16 patients with relapsed/refractory ccRCC who received CTX130 in a phase I, multicenter, first-in-human clinical trial. No patients encountered dose-limiting toxicity, and disease control was achieved in 81.3% of patients. One patient remains in a durable complete response at 3 years. Finally, we report on a next-generation CAR T construct, CTX131, in which synergistic potency edits to CTX130 confer improved expansion and efficacy in preclinical studies. These data represent a proof of concept for the treatment of ccRCC and other CD70+ malignancies with CD70-targeted allogeneic CAR T cells. SIGNIFICANCE Although the role of CAR T cells is well established in hematologic malignancies, the clinical experience in solid tumors has been disappointing. This clinical trial demonstrates the first complete response in a patient with RCC, reinforcing the potential benefit of CAR T cells in the treatment of solid tumors.
Collapse
Affiliation(s)
- Sumanta K Pal
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California
| | - Ben Tran
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - John B A G Haanen
- Netherlands Cancer Institute, Amsterdam, the Netherlands
- Leiden University Medical Center, Leiden, the Netherlands
- Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | | | - Adrian Sacher
- Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
- Departments of Medicine and Immunology, University of Toronto, Toronto, Canada
| | - Nizar M Tannir
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Lihua E Budde
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California
| | - Simon J Harrison
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | | | - Sagar S Patel
- Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Luis Meza
- Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California
| | | | - Anna Ma
- CRISPR Therapeutics, Boston, Massachusetts
| | | | | | | | - Ellen B Gurary
- Formerly employed by CRISPR Therapeutics, Boston, Massachusetts
| | - Henia Dar
- CRISPR Therapeutics, Boston, Massachusetts
| | | | - Changan Guo
- Formerly employed by CRISPR Therapeutics, Boston, Massachusetts
| | | | | | - Phuong K Morrow
- Formerly employed by CRISPR Therapeutics, Boston, Massachusetts
| | - Neeraj Agarwal
- Division of Medical Onco-logy, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
| | - Samer A Srour
- University of Texas MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
2
|
Huang JF, Zhan T, Yu XL, He QA, Huang WJ, Lin LZ, Du YT, Pan YT. Therapeutic effect of Pleurotus eryngii cellulose on experimental fatty liver in rats. Genet Mol Res 2016; 15:15017805. [PMID: 26985922 DOI: 10.4238/gmr.15017805] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The aim of this study was to explore the therapeutic effect of Pleurotus eryngii cellulose on experimental fatty liver in rats. Rats were fed high-fat fodder to establish a rat fatty liver model, and were then fed different concentrations of Pleurotus eryngii cellulose for six weeks. Lipitor was used as a positive control. Measured levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), and total triglyceride (TG); the activity of malondialdehyde (MDA), superoxide dismutase (SOD), hepatic lipase (HL), and lipoprotein lipase; and liver histopathological changes. Successfully established rat fatty liver model after feeding high-fat fodder for one week. A diet of P. eryngii cellulose for six weeks significantly reduced ALT, AST, TC, and TG levels in rat serum (P < 0.01); TC and AST levels in P. eryngii cellulose high-dose group and Lipitor group were not significantly different from those of the control (P > 0.05). SOD activity increased significantly, while MDA and HL activity decreased (P < 0.05); fatty degeneration and fat accumulation both decreased in hepatic tissue. Hepatic protection of P. eryngii cellulose showed dose-related effect. P. eryngii cellulose can affect lipid metabolism, having therapeutic effects on fatty liver in rats.
Collapse
Affiliation(s)
- J F Huang
- Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
| | - T Zhan
- Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
| | - X L Yu
- Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
| | - Q A He
- Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
| | - W J Huang
- Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
| | - L Z Lin
- Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
| | - Y T Du
- Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
| | - Y T Pan
- Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian, China
| |
Collapse
|